Medibio Ltd. (MDBIF: OTCQB) | Medibio completes heavily oversubscribed institutional chain for $13.9 million to accelerate commercialisation


  • Placement completed, with oversubscriptions supposed adult to $13.9 Million
  • Fidelity Investments follows on to say 10.6% tenure of a Company
  • IFM Investors and Regal FM to turn estimable shareholders post-transaction
  • Medibio now entirely saved to pursue assertive commercialisation and IP strategy

SYDNEY, Australia and MINNEAPOLIS, Oct. 12, 2017 (GLOBE NEWSWIRE) — Medibio Limited (ASX:MEB)(OTCQB:MDBIF) is gratified to announce that it has perceived organisation commitments to lift $13.9 million around a chain of 38,736,640 typical shares during a cost of $0.36 per share.  The chain will be conducted in a singular tranche regulating a Company’s existent chain ability underneath ASX Listing Rule 7.1 and 7.1A.

The supports will concede a Company to:

  • Build out organisational infrastructure for product commercialisation
  • Establish mandate and contrast of products and products underneath growth for destiny marketplace verticals
  • Development of record height and infrastructure, including engineering capability, to support commercialisation
  • Position Medibio for regulatory approvals on destiny products

Aesir Capital Pty Ltd acted as Sole Lead Manager to a transaction.  

About Medibio Limited

Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health record association that has pioneered a use of design biometrics to support in a screening, diagnosing, monitoring and government of basin and other mental health conditions.   The association was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN and Palo Alto, CA.  Medibio is listed on a Australian Securities Exchange Ltd and trades on a OTCQB Venture Market and

Additional avowal compulsory by inventory order 3.10.5A
In suitability with inventory order 3.10.5A in propinquity to shares released underneath a Company’s 7.1A ability sum of a chain are:

Effect of raising
The outcome of a announced lifting on a collateral structure of a Company is set out below.

The Company believes a advantages from supports lifted in this chain during a bonus to a 15-day VWAP of 11.9% transcend a inability of shareholders to participate.  The chain was not underwritten and approach costs of a lifting are adult to 7.5% of supports raised.

Further Information: Website:
Medibio Shareholder Enquiries:
Jack Cosentino
CEO and Managing Director
Medibio Limited
T: +1 (952) 465 4787

Australian Media Enquiries:
Peter Taylor
NWR Communications
T: +61 (0) 412 036 231

Primary Logo

This entry was posted in Think Pink! and tagged . Bookmark the permalink.